

Creative Cancer Concepts Inc.

Creative Cancer Concepts, Inc.

705 North Goliad

Rockwall, TX 75087


972-772-4104

e-mail: c3administrator@creativecancerconcepts.com

**Pearls of Wisdom from People Living with Cancer...
Improving the Management of Chemotherapy Induced Nausea**

Selected References

- Bloechl-Daum, B., Deuson, R.R., Mavros, P., Hansen, M. & Herrstedt, J. (2006). Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. *Journal of Clinical Oncology*, 24(27), 4472-4478.
- Borjesson, S. (2007). Antiemetic interventions: Using research evidence in daily clinical practice [Abstract S-23, 663]. *Supportive Care in Cancer*, 15(6).
- Byar, K.L., Berger, A.M., Bakken, S.L. & Cetak, M.A. (2006). Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. *Oncology Nursing Forum*, 33(1), E18-26.
- Coates, A., Abraham, S. Kaye, S.B., Sowerbutts, T., Frewin, C., Fox, R.M. et al. (1983). On the receiving end – Patient perception of the side-effects of cancer chemotherapy. *European Journal of Cancer Clinical Oncology*, 19, 203-208.
- Cohen, L., deMoor, C.A., Eisenberg, P., Ming, E.E. & Hu, H. (2007). Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings. *Supportive Care in Cancer*, 15(5), 497-503.
- Decker, G., DeMeyer, E.S. & Kisko, D. (2006). Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving emetogenic chemotherapy. *Journal of Supportive Oncology*, 4(1), 35-41, 52.
- Dibble, S.L., Isreal, J., Nussey, B., Casey, K. & Luce, J. (2003). Delayed chemotherapy-induced nausea in women treated for breast cancer. *Oncology Nursing Forum*, 30(2), E 40-47.
- Dibble, S.L., Luce, J., Cooper, B.A., Israel, J., Cohen, M., Nussey, B. et al. (2007). Acupressure for chemotherapy-induced nausea and vomiting: A randomized clinical trial. *Oncology Nursing Forum*, 34(4), 813-20.
- Einhorn, L.H., Brames, M.J., Dreicer, R., Nichols, C.R., Cullen, M.T., & Bubalo, J. (2007). Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. *Supportive Care in Cancer*, [Epub ahead of print].



Creative Cancer Concepts Inc.

Creative Cancer Concepts, Inc.


705 North Goliad

Rockwall, TX 75087

972-772-4104

e-mail: c3administrator@creativecancerconcepts.com

- Eisenberg, P., Figueroa-Vadillo, J., Zamora, R., Charu, V., Hajdenber, J., Cartmell, A. et al. (2003). Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT₃ receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. *Cancer*, 98, 2473–2482.
- Ernst, E., Pittler, M.H., Wider, B. & Boddy, K. (2007). Complementary/alternative medicine for supportive cancer care: Development of the evidence-base. *Supportive Care in Cancer* 15, 565-568.
- Gralla, R., Lichinitser, M., Van der Vegt, S., Sleeboom, H., Mezger, J. Peschel, C. et al. (2003). Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. *Annals of Oncology*, 14, 1570–1577.
- Griffin, A.M., Butow, P.N., Coates, A.S., Childs, A.M., Ellis, P.M., Dunn, S.M. et al. (1996). On the receiving end: Patient perceptions of the side effects of cancer chemotherapy in 1993. *Annals of Oncology*, 7, 189-195.
- Grote, T., Hajdenberg, J., Cartnell, A., Ferguson, S., Ginkel, A. & Charu, V. (2006). Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonestron, dexamethasone, and aprepitant. *Journal of Supportive Oncology*, 4(8), 403-408.
- Grunberg, S.M., Deuson, R.R., Mavros, P., Gerling, O., Hansen, M., Cruciani, G. et al. (2004). Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. *Cancer*, 100, 2261–2268.
- Grunberg, S.M., Osoba, D., Hesketh, P.J., Gralla, R.J., Borjeson, S., Rapoport, B. et al. (2005). Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. *Supportive Care in Cancer*, 13, 80-84.
- Grunberg, S.M., Dugan, M., Muss, H.B., Wood, M., Burdette-Radoux, S. & Weisberb, T. (2007). Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy. *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 9111.



Creative Cancer Concepts Inc.

Creative Cancer Concepts, Inc.


705 North Goliad

Rockwall, TX 75087

972-772-4104

e-mail: c3administrator@creativecancerconcepts.com

- Hickok, J.T., Roscoe, J.A., Morrow, G.R., Kind, D.K., Atkins, J.N. & Fitch, T.R. (2003). Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: A University of Rochester James P. Wilmot Cancer Center community clinical oncology program study of 360 cancer patients treated in the community. *Cancer*, 97(11), 2880–2886.
- Hickok, J.T., Roscoe, J.A., Morrow, G.R., Bole, C.W., Zhao, H., Hoelzer, K.L. et al. (2005). 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: A URCC CCOP randomized controlled trial. *Lancet Oncology*, 6(10), 765-772.
- Hofman, M., Morrow, G.R., Roscoe, J.A., Hickok, J.T., Mustian, K.M., Moore, D.F. et al. (2004). Cancer patients' expectations of experiencing treatment-related side effects: A University of Rochester Cancer Center community clinical oncology program study of 938 patients from community practices. *Cancer*, 101(4), 851-857.
- Liau, C.T., Chu, N.M., Liu, H.E., Deuson, R., Lien, J. & Chen, J.S. (2005). Incidence of chemotherapy-induced nausea and vomiting in Taiwan: Physicians' and nurses' estimation vs. patients reported outcomes. *Supportive Care in Cancer*, 13, 277-286.
- Neymark, N. & Crott, R. (2005). Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: A retrospective analysis of three clinical trials. *Supportive Care in Cancer*, 13, 812-818.
- Lindley, C., Goodin, S., McCune, J., Kane, M., Amamoo, M.A., Shord, S. et al. (2005). Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: Comparison of ondansetron, prochlorperazine, and dexamethasone. *American Journal of Clinical Oncology*, 28(3), 270-276.
- Martin, C.G., Rubenstein, E.B., Elting, L.S., Kim, Y.J. & Osoba, D. (2003). Measuring chemotherapy-induced nausea and emesis. *Cancer*, 98(3), 645-655.
- Miller, R.C., Galvan, M., Gittos, M.W., van Giersbergen P.L.M., Moser, P.C. & Fozard, J.R. (1993). Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT₃ receptors. *Drug Development Research*, 28, 87-93.
- Rojas, C., Stathis, M., Thomas, A., Massuda, E., Alt, J., Zhang, J. et al. (2007). Palonosetron, in contrast to ondansetron and granisetron, exhibits two-site binding to the 5-HT₃ receptor and causes long lasting functional inhibition even after dissociation [Abstract P-017, 663]. *Supportive Care in Cancer*, 15(6).



Creative Cancer Concepts Inc.

Creative Cancer Concepts, Inc.

705 North Goliad

Rockwall, TX 75087

972-772-4104

e-mail: c3administrator@creativecancerconcepts.com

Rubenstein, E.B., Gralla, R.J., Eisenberg, P., Sleeboom, H., Vtoraya, O., Macciocchi, A. et al (2003). Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute & delayed chemotherapy-induced nausea and vomiting (CINV): Combined results of two phase III trials [Abstract 2932]. *Proceedings of American Society of Clinical Oncology*, 22, 729.

Schwartzberg, L.S. (2007). Chemotherapy-induced nausea and vomiting: Which antiemetic for which therapy? *Oncology* 21(8), 946-953.

Shelke, A.R., Roscoe, J.A., Morrow, G.R., Hickok, J. T., Bushunow, P., Matteson, S. et al. (2003). Patient's pre-clinic expectancy of nausea predicts the likelihood of severe nausea from chemotherapy [Abstract A-21]. *Supportive Care in Cancer*, 11, 392.

Slatkin, N.E. (2007). Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: Beyond prevention of acute emesis. *The Journal of Supportive Oncology*, 5(5, supplement 3), 1-9.

Sun, C.C., Bodurka, D.C., Weaver, C.B., Rasu, R., Wolf, J.K., Bevers, M.W. et al. (2005). Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. *Supportive Care in Cancer*, 13(4), 219-227.

Tipton, J.M., McDanie, R.W., Barbour, L.B., Johnston, M.P., Kayne, M., LeRoy, P. et al. (2007). Putting evidence into practice: Evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. *Clinical Journal of Oncology Nursing*, 11(1), 69-78.

Weaver, C., Schiech, L., Held-Warmkessel, J., Kedziera, P., Haney, E., DiLullo, G. et al. (2006). Risk for unplanned hospital readmission of patients with cancer: Results of a retrospective medical record review. *Oncology Nursing Forum*, 33(3), E44-52.

Wong, E.H.F., Clark, R., Leung, E., Loury, D., Bonhaus, D.W., Jakeman, L. et al. (1995). The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT₃ receptor, in vitro. *British Journal of Pharmacology*, 114(4), 851-859.

The material in this program was compiled by Creative Cancer Concepts, Inc. with an educational grant from MGI PHARMA, INC. This information should not be used by clinicians in the management of patients without evaluation of the patients' condition, possible contraindications, review of the manufacturer's product information, and consultation with recommendations of other authorities.

©2007 Creative Cancer Concepts, Inc. All rights reserved.